SCHEMBL2293345

SCHEMBL2293345

OCCCc1nc2c(o1)-c1ccccc1Oc1ccccc1-2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 11/20 0.41
NR4A2 P43354 11/20 0.41
RXRB P28702 10/20 0.41
RXRG P48443 5/20 0.41
NR4A1 P22736 3/20 0.39
NR4A3 Q92570 3/20 0.39
AOC3 Q16853 1/20 0.38
PTGS1 P23219 2/20 0.37
EPHX2 P34913 2/20 0.37
PTGS2 P35354 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ABCC4 O15439 1/20 0.37
C5 P01031 1/20 0.37
LMNA P02545 1/20 0.37
CHRM2 P08172 1/20 0.37
CYP3A4 P08684 1/20 0.37
CHRM1 P11229 1/20 0.37
DRD2 P14416 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2289730 0.81 RXRA (0.62) RXRANR4A2RXRBRXRGNR4A1
SCHEMBL6407346 0.79 NR4A2 (0.39) RXRANR4A2RXRBRXRGNR4A1
SCHEMBL2292267 0.79 ELANE (0.37) RXRANR4A2RXRBRXRGNR4A1
SCHEMBL2290286 0.79 RXRA (0.40) RXRANR4A2RXRBRXRGNR4A1
SCHEMBL2290421 0.76 NR4A2 (0.38) RXRANR4A2RXRBRXRGNR4A1
SCHEMBL5182953 0.76 NR4A2 (0.38) RXRANR4A2RXRBRXRGNR4A1
SCHEMBL2293918 0.76 KDM4E (0.51) RXRANR4A2RXRBRXRGNR4A1
SCHEMBL18063471 0.73 NR4A2 (0.71) RXRANR4A2RXRBRXRGNR4A1
SCHEMBL5700661 0.72 RXRA (0.49) RXRANR4A2RXRBRXRGNR4A1
SCHEMBL2296178 0.70 MAPK13 (0.42) RXRANR4A2RXRBRXRGPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1684766-B1 USE OF 3-AZA-1-OXA-DIBENZO i e,h /i AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEAS AND DISORDERS GLAXOSMITHKLINE ZAGREB (HR) 2007-06-27 EP claimed
US-7232815-B2 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof GLAXOSMITHKLINE (HR) 2007-06-19 US claimed
US-20070111990-A1 3-Aza-1-oxa-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2007-05-17 US claimed
EP-1492797-B1 1-OXA-3-AZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PRODUCTION THEREOF PLIVA ISTRAZIVACKI INST D O O (HR) 2006-03-15 EP claimed
US-20050148576-A1 1-Oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-07-07 US claimed
US-20050130956-A1 1-oxa 3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-06-16 US claimed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed
US-20110200618-A1 ERBB4 INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROPSYCHIATRIC DISORDERS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2011-08-18 US disclosed
WO-2009103072-A2 ERBB4 INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROPSYCHIATRIC DISORDERS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2009-08-20 WO disclosed
EP-1684766-B1 USE OF 3-AZA-1-OXA-DIBENZO i e,h /i AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEAS AND DISORDERS GLAXOSMITHKLINE ZAGREB (HR) 2007-06-27 EP disclosed
US-7232815-B2 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof GLAXOSMITHKLINE (HR) 2007-06-19 US disclosed
US-20070111990-A1 3-Aza-1-oxa-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2007-05-17 US disclosed
EP-1684766-A1 USE OF 3-AZA-1-OXA-DIBENZO i e,h /i AZULENES FOR TH E MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEAS AND DISORDERS PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2006-08-02 EP disclosed
US-20050148576-A1 1-Oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-07-07 US disclosed
US-20050130956-A1 1-oxa 3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-06-16 US disclosed
WO-2005049036-A1 USE OF 3-AZA-1-OXA-DIBENZO [e,h] AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEAS AND DISORDERS PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-06-02 WO disclosed
EP-1492797-A1 1-OXA-3-AZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PRODUCTION THEREOF PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2005-01-05 EP disclosed
WO-2003084964-A1 1-OXA-3-AZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PRODUCTION THEREOF PLIVA - ISTRAZIVACKI INSTITUT D.O.O. (HR) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148576-A1 1-Oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof TNF, IL1A, IL1B RXRA 2092/4885NR4A2 2164/4885RXRB 2214/4885
US-20050130956-A1 1-oxa 3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof TNF, IL1A, IL1B RXRA 1888/4885NR4A2 1721/4885RXRB 2025/4885
US-20070111990-A1 3-Aza-1-oxa-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders AZI2, DBH, BCHE RXRA 2049/4885NR4A2 728/4885RXRB 2018/4885
US-20110200618-A1 ERBB4 INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROPSYCHIATRIC DISORDERS ERBB4, ERBB3, ERBB2 RXRA 2231/4885NR4A2 140/4885RXRB 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.